Multifunctional proligands for Alzheimer's disease therapy

MEDI 289

Lauren E Scott, lescott@chem.ubc.ca1, David E. Green1, Tim Storr, tstorr@stanford.edu2, Meryn L. Bowen, mbowen@chem.ubc.ca1, Michael Merkel1, Gavin H Tansley3, Harvey Schugar, hschugar@gmavt.net4, Cheryl L. Wellington, cheryl@cmmt.ubc.ca3, and Chris Orvig, orvig@chem.ubc.ca1. (1) Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, (2) Department of Chemistry, Stanford University, 333 Campus Drive, Stanford, CA 94305-5080, (3) Centre for Molecular Medicine and Therapeutics, University of British Columbia, 980 W 28th Ave, Vancouver, BC V5Z 4H4, (4) Department of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey, 610 Taylor Road, Piscataway, NJ 08854-8087
The brain pathology of Alzheimer's disease is typified by the presence of insoluble protein plaques (of beta-amyloid peptide, Aß) associated with elevated levels of brain metal ions such as Cu, Zn and Fe. Dysfunctional interactions of the aggregated peptide and redox-active metal ions (Cu, Fe) are implicated in the development of highly oxidative conditions in the brain, leading to neurological decline; thus, small molecule metal-binding agents with antioxidant activity have been developed as potential Alzheimer's therapeutics. Targeting to the brain through appended sugar moieties completes the multifunctionality of these new compounds. The synthesis, characterization and in vitro assay of these pro-drugs will be discussed.
 

Poster Session
7:00 PM-9:00 PM, Wednesday, August 22, 2007 BCEC -- Exhibit Hall - B2, Poster

Division of Medicinal Chemistry

The 234th ACS National Meeting, Boston, MA, August 19-23, 2007